Group 1 - Ningde Times has set the H-share offering price at HKD 263.00 per share, with an additional issuance of 17,684,100 shares, representing approximately 15.0% of the total shares available for subscription [1] - The additional shares will be allocated based on an initial ratio of 7.5% for the Hong Kong public offering and 92.5% for the international offering [1] - The H-shares are expected to commence trading on the Hong Kong Stock Exchange on May 20, 2025, at 9:00 AM [1] Group 2 - Moody's has downgraded the U.S. credit rating from AAA to AA1, impacting market sentiment [2] - Major U.S. stock indices showed positive performance, with the Dow Jones up 331.99 points (0.78%) and the S&P 500 up 41.45 points (0.70%) [2] - The Nasdaq China Golden Dragon Index rose by 4.56% over the week, indicating a positive trend for Chinese concept stocks [2] Group 3 - The Hang Seng Index Company announced the quarterly review results, increasing the number of constituent stocks from 83 to 85, with BYD included in the Hang Seng Tech Index [3] Group 4 - The Central Committee of the Communist Party and the State Council have mandated that government procurement of vehicles should prioritize domestic and new energy vehicles [4] Group 5 - The revised regulations prohibit high-end dishes and alcohol in official work meals, emphasizing cost control in government receptions [5] Group 6 - The Financial Secretary of Hong Kong stated that global funds are increasingly flowing towards leading innovative technology companies and future industries [6] Group 7 - The China Securities Regulatory Commission encourages private equity funds to participate in mergers and acquisitions of listed companies, with adjustments to lock-up periods for investments [7][8] Group 8 - WuXi AppTec's subsidiary, Hanbang Technology, was listed on the Shanghai Stock Exchange on May 16, 2025 [9] Group 9 - Weichai Power expects significant growth in sales of its M-series large-bore engines and data center products, driven by strong industry demand [10] Group 10 - Shandong Xinhua Pharmaceutical is the largest producer of ibuprofen raw materials in China, with an annual production capacity exceeding 8,000 tons, accounting for 40% of global capacity [11] - The company holds a 62.66% market share in China and exports 60% of its total production, primarily to high-end markets in Europe and the U.S. [11]

点评：中信证券表示，强制性国标落地将推动AEBS渗透率快速提升(目前乘用车装配率约30%)，2025年有望突破60%，带动毫米波雷达、摄像头、域控制器 等核心部件需求放量。相关行业分析师表示，目前我国AEBS整体装配率不足，尤其那些入门级车型，几乎都没装配AEBS。据乘联会此前发布的数据，今 年1-2月我国乘用车整体装配率为56.5%，其中新能源乘用车装配率相对较高，已经达到62.9%。AEBS的装配率还与车辆价格呈正相关，32万元以上的高端 车型，整体装配率已经超过93%，而8万元以下的入门级车型，装配率仅2.6%。未来随着新规的落地，AEBS还有很大的提升空间，相关产业国产化有望进一 步加速。 4、核聚变 | 中核集团5月16日官宣，我国核技术应用领域迎来重大里程碑时刻——首批商用堆产碳-14同位素从中核集团旗下中国核电投资控股的秦山核电 基地正式发运至客户手中。该产品是我国首个同位素生产技术品牌"和福一号"诞生后的首批量产成果，标志着我国碳-14同位素实现了从自主研发、自主生 产到市场化供应的全产业链贯通，彰显了该技术生产体系的自主化、规模化和品牌化优势，开启了我国同位素产业的新篇章。 点评：证券时报表 ...

Market Overview - A total of 71 stocks hit the daily limit up in the A-share market, with 57 stocks hitting the limit after excluding 14 ST stocks, resulting in an overall limit-up rate of 68.27% [1] Top Performers - Hongtong Gas had the highest limit-up order volume at 398,700 hands, followed by Ningbo Shipping, Chunxing Precision, and Zhongchao Holdings with limit-up order volumes of 356,500 hands, 255,500 hands, and 202,500 hands respectively [2] - In terms of consecutive limit-up days, *ST Yazhen achieved 9 consecutive limit-ups, Chengfei Integration had 8, and five stocks including Ningbo Shipping and Nanjing Port had 4 consecutive limit-ups [2] Sector Highlights Clean Energy - Hongtong Gas, a clean energy company, is positioned to benefit from the national "dual carbon" strategy, with natural gas expected to accelerate its replacement of high-carbon energy sources like coal and oil, particularly in the logistics heavy truck market [3] Automotive Parts - Several automotive parts stocks hit the limit up, including Haoen Automotive Electronics, Chunxing Precision, Tianqi Mould, and others, indicating strong market interest in this sector [4] - Chunxing Precision is actively expanding its new energy vehicle business and increasing production capacity [5] - Tianqi Mould has a strong presence in the automotive mould sector, serving major joint venture and independent automotive brands [6] Robotics - Stocks like Lijun Co., Wan'an Technology, and Junsheng Electronics also saw limit-up, reflecting growth in the robotics sector [7] - Lijun Co. focuses on intelligent equipment manufacturing, while Wan'an Technology's wireless charging products are applicable in various robotic fields [7] Pharmaceuticals - Pharmaceutical stocks such as Tuoxin Pharmaceutical, Hasanlian, and Xinhua Pharmaceutical also reached limit-up [8] - Tuoxin Pharmaceutical is making progress in raw material drug registrations, with two applications accepted by the National Medical Products Administration [8] - Hasanlian has maintained a leading market share in chemical drug formulations for over 20 years [9] - Xinhua Pharmaceutical has established multiple large R&D platforms in the innovative drug field [10] Institutional Activity - Institutions net bought over 100 million in stocks like Kuaijingtong, Hongbaoli, and Qingdao King [11][12] - Specific net buying amounts include 112 million in Kuaijingtong and 68.61 million in Hongbaoli [13]

16日，A股盘中弱势震荡整理，北证50指数逆市上扬；港股盘中走势疲弱，两大股指小幅走低。 具体来看，沪指盘中弱势下探，深证成指、创业板指盘中一度翻红。截至收盘，沪指跌0.4%报3367.46点，深证成指微跌0.07%报10179.6点，创业板指跌0.19%报 2039.45点，上证50指数跌0.86%，北证50指数涨0.49%，沪深北三市合计成交11242亿元，较昨日减少逾660亿元。 场内约3000股飘红，汽车产业链股爆发，豪恩汽电20%涨停，亚太股份、路畅科技、万安科技等均涨停；医药板块走高，森萱医药20%涨停，拓新药业、哈三联等 连续两日涨停；可控核聚变概念拉升，中洲特材、常辅股份盘中创出新高；人形机器人概念再度活跃，兆丰股份、精锻科技等涨超10%；值得注意的是，多只强势 股持续受到资金追捧，如成飞集成（收获8连板，利君股份近8日斩获7个涨停板，中毅达3月以来已累计大涨超260%。而金融、酿酒等权重板块却集体回调。 港股方面，阿里巴巴、恒生银行、信义光能等跌超3%，绿茶集团上市首日跌逾12%；网易大涨约13%，地平线机器人涨超5%。 医药板块盘中发力走高，创新药、减肥药概念等表现亮眼。截至收盘，森萱医药 ...

金十数据5月16日讯，港股全天窄幅震荡，恒指收跌0.46%，报23345.05点。恒生科技指数收跌0.31%， 报5281.34点。截至今日收盘，恒指大市成交额1907.22亿港元。盘面上，线上零售商板块领跌，蚂蚁金 服概念股走低，创新药反弹，黄金股回暖，汽车股局部走强。个股方面，网易(09999.HK)涨13%，第四 范式(06682.HK)涨11.6%，山东新华制药股份(00719.HK)涨近9%，京东健康(06618.HK)、中国生物制药 (01177.HK)涨3.85%，比亚迪股份(01211.HK)、石药集团(01093.HK)涨超3%，阿里巴巴(09988.HK)跌 4.27%，美团(03690.HK)跌近3%。绿茶集团(06831.HK)尾盘直线下挫，上市首日收跌12.52%，成交额超 6亿港元。 港股收评：网易绩后大涨13% 创新药板块反弹 新华制药涨近9% ...

Market Overview - The three major A-share indices collectively declined, with the Shanghai Composite Index down 0.42%, the Shenzhen Component Index down 0.07%, and the ChiNext Index down 0.19%, while the North Star 50 Index increased by 0.49% [1] - The total market turnover was 1,124.1 billion, a decrease of 66.3 billion compared to the previous day [1] - Over 3,000 stocks in the market experienced an increase [1] Sector Performance - The PEEK materials, controllable nuclear fusion, automotive parts, and chemical pharmaceuticals sectors saw the largest gains [1] - The automotive industry chain sector experienced a significant surge, with stocks such as Haon Auto Electric (301488), Spring Engineering (002547), and Tianqi Mould (002510) hitting the daily limit [1] - The chemical pharmaceuticals sector continued to rise in the afternoon, with multiple stocks including Tuoxin Pharmaceutical (301089), Hasa Lian (002900), and Xinhua Pharmaceutical (000756) also reaching the daily limit [1] - The logistics sector faced adjustments, with Huaguang Source Sea dropping over 10% during trading, and New Ning Logistics (300013) and Haicheng Bangda (603836) showing significant declines [1] - The chemical fiber concept stocks underperformed, with Jilin Carbon Valley, Jiangnan High Fiber (600527), and Suzhou Longjie (603332) leading the declines [1]

中证网讯5月16日，A股创新药板块午后拉升，截至14:40，热景生物涨超11%，新华制药（000756）此 前封板，迈威生物涨超8%，天士力（600535）、海创药业跟涨。 创新药ETF(159992)及其联接基金(A类：012781；C类：012782)跟踪的CS创新药指数(931152.CSI)，选 取主营业务涉及创新药研发的上市公司作为待选样本，按照市值排序选取不超过50家最具代表性公司作 为样本股，反映创新药产业上市公司的整体表现。自2020年成立以来，创新药ETF获得资金高度关注。 截至2025年5月12日，基金规模达到了110.23亿元，流动性充足。 从整体来看，将进一步加速推进数字化、智能化技术在医药工业领域的推广应用，以人工智能为代表的 新一代信息技术与医药研发融合日益深入。 从细分领域来看，医药工业数智化全链条传导，利好医药产业链中的医药工业研发和生产、人工智能工 具提供者、医药行业信息化基础设施建设等环节。 在此背景下，银华旗下创新药主题基金，聚焦创新药行业龙头，涵盖化学制药、生物制品、医疗服务等 行业，或可助力投资者把握创新药数智化发展机遇。 近日，工业和信息化部、商务部、国家卫生健康委 ...

2024年，原料药板块盈利能力迎来全面改善，毛利率同比提升1.58个百分点至38%，净利率大幅攀升 4.97个百分点至12.79%，创下近三年新高。分季度看，Q4成为全年亮点，毛利率同比跳涨5.47个百分点 至40.29%，净利率同比提升13.89个百分点。 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 2024年，32家原料药上市公司交出了一份稳健的成绩单，全年实现营业收入1176.77亿元，同比增长 6.74%，成功扭转了2023年因价格下行和去库存导致的低迷态势。分季度来看，行业呈现出显著的"前 低后高"特征。Q1营收同比微降0.56%，但从Q2开始，随着全球下游厂商去库存周期接近尾声，叠加部 分新产品进入放量期，Q2-Q4营收同比分别增长9.04%、12.64%、8.76%。 值得注意的是，尽管2025年Q1营收同比小幅下滑0.48%至295.46亿元，但环比仍增长5.77%，显示出行 业在经历阶段性调整后逐步企稳的态势。这一表现与全球医药供应链的修复节奏基本同步，尤其是欧美 市场对原料药需求的温和回升，为行业提供了支撑。 利润端的表现则更具爆发力，2024年原料药板块归母 ...

格隆汇5月16日｜港股药品股拉升明显，其中，山东新华制药一度大涨近16%表现抢眼，天大药业、德 琪医药涨超6%，三生制药、远大医药涨5.6%，石药集团、信达生物涨超2%。 【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容 的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱： news_center@staff.hexun.com | 代码 | 名称 | 最新价 | 涨跌幅 ▽ | | --- | --- | --- | --- | | 00719 | 山东新华制药股 | 6.260 | 9.82% | | 00932 | 顺腾国际控股 | 0.025 | 8.70% | | 00455 | 天大药业 | 0.152 | 6.29% | | 06996 | 德琪医药-B | 3.440 | 6.17% | | 01530 | 三生制药 | 12.100 | 5.77% | | 00512 | 远大医药 | 8.650 | 5.62% | | 00950 | 李氏大药厂 | 1.400 | 4.48% | | 0689 ...

港股制药板块拉升，山东新华制药（000756）股份涨超10%，凯莱英（002821）涨超4%，信达生物、 翰森制药、远大医药跟涨。 无需港股通，A股账户就能T+0买港股>> ...